Telomere length is one of the most recognisable biomarkers in aging research, and one hydrogen trial reported that six months of hydrogen-rich water increased it in adults aged 70 and over while it decreased in the control group[1]. That is a striking claim. It is also a single result at p equal to 0.049, in a trial where most measured outcomes showed no difference at all, and both halves of that sentence deserve equal weight.
The trial
The study was a randomized controlled trial in older adults, with a mean age of 76.0 years, mean weight 78.2 kilograms and mean height 167.5 centimetres[1]. Participants received either hydrogen-rich water at 15 parts per million of hydrogen, or a control drink at zero parts per million, over a six-month intervention period.
Six months is long by the standards of this literature. Most hydrogen trials run four to eight weeks, which is barely enough time for slow biological processes to register. Aging biomarkers move slowly, so a six-month window is one of the design strengths here.
The measurement panel was unusually broad. It covered molecular markers in blood spanning DNA and chromosomes, nutrient sensing, protein and lipid metabolism, oxidative stress and mitochondria, cell senescence and inflammation, plus brain metabolism, cognitive functioning, physical function and body composition, resting blood pressure, facial skin features, sleep outcomes and health-related quality of life[1]. The trial is registered at ClinicalTrials.gov under NCT04430803.
Why breadth is a double-edged design choice
Measuring dozens of outcomes across many biological domains maximises the chance of detecting a real effect wherever it happens to be. It also maximises the chance of detecting something that is not there.
The reason is arithmetic. If you test enough outcomes at a significance threshold of 0.05, some will cross that threshold by chance even when nothing is happening. Test twenty independent outcomes with no true effects and you should expect roughly one apparent hit. This trial tested considerably more than twenty.
That does not mean the positive findings are false. It means that a result sitting just inside the threshold, in a study with a large outcome panel, is weaker evidence than the same p-value would be in a study with one pre-specified primary endpoint. This is the central interpretive issue for the whole trial, so it is worth stating before the results rather than after.
What the trial found
A significant treatment-by-time interaction was found for telomere length at p equal to 0.049[1]. Length increased in the hydrogen group from 0.99 plus or minus 0.15 at baseline to 1.02 plus or minus 0.26 at follow-up, and decreased in the control group from 0.92 plus or minus 0.27 to 0.79 plus or minus 0.15.
Look at the standard deviations rather than only the means. The hydrogen group’s follow-up value is 1.02 with a standard deviation of 0.26, meaning individual results were spread widely around that average. The change in the hydrogen group, from 0.99 to 1.02, is small relative to that spread. Most of the group separation comes from the control group declining, not from the hydrogen group rising.
On DNA methylation, expression of TET2, an enzyme involved in the methylation process, increased in both groups at follow-up, but the increase was significantly larger in the hydrogen group, at p equal to 0.040[1]. Hydrogen went from 0.81 plus or minus 0.52 to 1.62 plus or minus 0.66; control went from 1.13 plus or minus 0.82 to 1.76 plus or minus 0.87.
The overall degree of DNA methylation showed only a trend, at p equal to 0.166, which is not significant[1]. The paper describes this as a strong trend. A p-value of 0.166 is not a strong trend by any conventional standard, and readers should treat that particular characterisation with scepticism while accepting the underlying number as reported.
On brain metabolism, hydrogen-rich water was superior to control for increasing brain choline and N-acetylaspartate levels in the left frontal grey matter, brain creatine in the right parietal white matter, and N-acetylaspartate in the right parietal mesial grey matter, all at p less than 0.05[1].
On physical function, chair-stand performance improved significantly after hydrogen intervention compared with control water, at p equal to 0.01[1]. This is the strongest p-value in the trial and the outcome with the most obvious real-world meaning: the chair-stand test measures how many times a person can rise from a seated position in a fixed period, and it is a standard clinical measure of lower-body strength and functional independence in older adults.
For everything else measured, no significant differences were found between interventions, at p greater than 0.05[1]. That includes cognitive functioning, body composition, blood pressure, facial skin features, sleep outcomes and health-related quality of life.
Ranking the findings by how much they should convince you
The chair-stand result is the most credible finding in the trial. It has the lowest p-value at 0.01, it is an objective performance measure rather than a self-report, and it maps directly onto something that matters for people in their seventies.
The brain metabolite findings are next. They are objectively measured by imaging rather than reported by participants, and several appeared together across different brain regions, which is harder to explain as coincidence than a single isolated hit. What they mean functionally is unclear, particularly given that cognitive functioning showed no significant difference in the same trial. Metabolite changes without cognitive changes are a lead, not an outcome.
The telomere finding is the weakest of the positive results despite being the most quotable. It sits at 0.049, it comes from a large outcome panel, the within-group change in the hydrogen arm is small relative to its own variability, and telomere length measurement is technically sensitive to assay conditions.
The honest summary is the one the numbers support: one solid functional result, several interesting mechanistic signals, one much-quoted borderline result, and no effect on most of what was measured.
The mechanism this rests on
The rationale connects to hydrogen’s proposed role as a selective antioxidant that reduces cytotoxic oxygen radicals without suppressing the reactive species involved in normal cell signalling[2]. Oxidative damage accumulates with age and is implicated in telomere attrition specifically, which makes a selective antioxidant a coherent thing to test against aging biomarkers.
Supporting this, the 24-week metabolic syndrome trial found that high-concentration hydrogen-rich water improved biomarkers of inflammation and redox homeostasis against placebo at p less than 0.05[3], establishing that oral hydrogen can shift redox markers in humans over a comparable timeframe.
The authors’ own conclusion is that because of hydrogen’s varied mechanisms of action, it could be recognised as a possible anti-aging agent addressing several hallmarks of aging, including loss of function and telomere shortening[1]. “Possible” is the operative word, and it is theirs.
What would make this convincing
Independent replication by a different group, in a larger sample, with telomere length or chair-stand performance pre-specified as the primary endpoint rather than sitting inside a broad panel. That design removes the multiple-comparisons problem entirely, and until it exists, this trial should be read as generating a hypothesis rather than confirming one.
Nothing about a six-month biomarker trial speaks to lifespan or healthspan, which would require following participants for years. Telomere length is a marker that correlates with aging, not a demonstrated lever on it.
The bottom line
Six months of hydrogen-rich water at 15 parts per million in adults aged 70 and over produced a significant improvement in chair-stand performance at p equal to 0.01, several brain metabolite increases, a larger rise in TET2 expression, and a telomere-length treatment-by-time interaction at p equal to 0.049[1]. Most other outcomes, including cognition, body composition, blood pressure and quality of life, showed no difference.
The functional strength result is the one worth paying attention to. The telomere headline is the one worth being most careful with.
References
- The effects of 6-month hydrogen-rich water intake on molecular and phenotypic biomarkers of aging in older adults aged 70 years and over: A randomized controlled trial. Experimental Gerontology, 2021
- Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nature Medicine, 2007
- The Effects of 24-Week, High-Concentration Hydrogen-Rich Water on Body Composition, Blood Lipid Profiles and Inflammation Biomarkers in Men and Women with Metabolic Syndrome. Diabetes, Metabolic Syndrome and Obesity, 2020
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
